Syngene reported 18% YoY growth in Q3FY25 net profit. Revenue rose 11% YoY. EBITDA margin improved to 31.4%. Company expects ...

Biocon advanced 2.41% to Rs 397.20 after its board is scheduled to meet on Monday, 27 January 2025, to consider and approve the raising of funds on a private placement basis.

BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2025 ,inter alia, to consider and approve Raising of Funds through issuance of Commercial ...

Synthetic biology startup Fermbox works in an asset-light business model and has raised $2.5 Mn so far to build its tech ...

India's Finance Minister will present the FY25-26 Union Budget on February 1, 2025. Analysts suggest focus on manufacturing, ...

The patent expiry of key drugs in 2025-26 will open up additional market space for Indian manufacturers of generics and ...

Biocon stock price is poised for a fresh breakout from its consolidation range of 320-395, following nearly three and a half ...

Reuters Nifty continues to climb a wall of worry as it looks to be in the final leg of its rally before heading for a ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Here's a list of buy/sell recommendations for today from three analysts: Ankush Bajaj, Raja Venkatraman, and MarketSmith ...

The Nity50 opened with a significant gap up of 102 points at 23,306.20. However, sellers intervened and pulled the index down ...

As the US remains the top market for the Indian pharmaceutical industry, experts in India are now expecting opportunities for ...